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Background: The efficacy and safety of extrafine beclomethasone dipropionate 100 mg/formo-
terol 6 mg (BDP/F HFA) pressurized metered dose inhaler (pMDI) in patients with moderate-to-
severe persistent asthma, has been demonstrated in randomised controlled trials (RCTs). The
aim of this prospective observational study was to assess real-life effectiveness in terms of
asthma control in smoking (most of the time excluded from RCTs) and non-smoking asthmatics.
Methods: Adult patients with persistent asthma, in whom treatment with an inhaled
corticosteroid/long-acting b2-agonist (ICS/LABA) combination is indicated, were included.
Pulmonary function (FEV1%pred or PEF absolute value), Asthma Control Questionnaire (ACQ)
and asthma control according to GINA criteria were measured at baseline as well as 2e8
months and >8e14 months after treatment initiation with BDP/F HFA.
Results: Overall, 619 patients were enrolled by 97 investigators. In the effectiveness cohort
(NZ 568), at baseline, smoking asthmatics (NZ 123) had higher ACQ6 (p < 0.0001) and lower
asthma control (pZ 0.021) than non-smoking asthmatics. Treatment with BDP/F HFA pMDI was
associated with significant (p < 0.0001) improvements in pulmonary function (þ7.1% in FEV1%
pred), ACQ6 (1.32) and GINA asthma control (improvement of control in 49.8% of patients).
Importantly, the same treatment benefits were observed in former or current smokers3322604; fax: þ32 9 3322341.
ent.be (G. Brusselle).
2 Elsevier Ltd. All rights reserved.
812 G. Brusselle et al.compared with non-smoking asthmatics. There was a reduction in the dose of ICS from
489  192 mg BDP extrafine equivalents at baseline to 265  125 mg after one year. The drug
was well-tolerated.
Conclusion: This prospective cohort study demonstrates the real-life effectiveness and safety
of BDP/F HFA in adult asthma patients, including smokers, in normal clinical practice.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Asthma represents a global public health issue due to the
high prevalence rates in the general population (ranging
from 1% to 18% in the different European countries and 300
million people worldwide) and the impact and burden of
asthma is even more pronounced due to the difficulty in
achieving full disease control.1,2 According to the Global
Initiative for Asthma (GINA), achieving and maintaining
asthma control should be the major goal of asthma care and
there is now good evidence that the clinical manifestations
of asthma, such as symptoms, sleep disturbances, limita-
tions of daily activity, impairment of lung function and use
of rescue medications, can be controlled with appropriate
treatment.3,4 The combination of a long-acting beta2-
agonist (LABA) and an inhaled corticosteroid (ICS) is
currently the preferred treatment when a medium dose of
ICS alone fails to achieve control of asthma in moderate to
severe asthmatic patients. The addition of a LABA to an ICS
in adult asthmatics indeed improves symptom scores and
lung function compared to monotherapy with ICS, whereas
it decreases nocturnal awakenings and the need for rescue
treatment with short-acting beta2-agonists (SABA).
3 In
addition, combination therapy of LABA and ICS reduces the
number of exacerbations and achieves asthma control more
rapidly and with a lower dose of ICS than if ICS is given
alone.3
The formulation of beclometasone dipropionate/for-
moterol (BDP/F; 100/6 mg) hydrofluoroalkane (HFA) in
pressurized metered dose inhaler (pMDI) is characterized by
extrafine particle size, which results in improved lung
deposition and allows for uniform treatment of inflamma-
tion and bronchoconstriction throughout the entire bron-
chial tree.5e8 The efficacy and safety of extrafine BDP/F
HFA (100/6 mg), 1 to 2 puffs twice daily, in patients with
moderate-to-severe persistent asthma, has been demon-
strated in double-blind randomised controlled clinical trials
(RCTs), versus placebo,9e11 versus fluticasone/salmeterol
125/25 mg pMDI12 and versus budesonide/formoterol 400/
12 mg dry powder inhaler (DPI).13
Results of RCTs, ensuring high adherence to treatment
and applying very selective inclusion/exclusion criteria,
provide currently the cornerstone of clinical evidence in
determining the efficacy of therapeutic interventions.
They, however, do not guarantee that a particular therapy
will be effective in the different patient populations seen in
daily clinical practice on a long-term basis.14 In the case of
asthma, the eligibility criteria in most RCTs eliminate an
estimated 95% of patients with a current diagnosis of
asthma, since they exclude smoking asthmatics and
patients who have co-morbidities, incomplete bronchodi-
lator reversibility or impaired pulmonary function.Moreover, the design of such RCTs rarely accounts for the
long-term factors that clinicians must consider, such as
adherence, inhaler technique, tolerability, and physician
and patient preferences. Observational studies can
complement the findings from RCTs by assessing treatment
effectiveness in real life and safety, in particular long-term
safety and rare adverse events, in patients encountered in
day-to-day clinical practice.4,15e18
The objective of this prospective observational one-year
cohort study was to evaluate the real-life effectiveness of
the extrafine BDP/F (100/6 mg) HFA pMDI formulation
(Inuvair or Foster, Chiesi Farmaceutica Spa, Parma, Italy)
in adult patients with moderate-to-severe persistent
asthma. Since conducting this study was a requirement of
the health care reimbursement official body in Belgium
(INAMI/RIZIV), the study was initiated shortly after the
introduction of the drug on the Belgian market. In accor-
dance with the updated GINA guidelines, we investigated
whether patients with moderate-to-severe persistent
asthma achieved or maintained good asthma control upon
treatment with extrafine BDP/F HFA in real life. Since
(current and former) smoking asthmatics are excluded from
classical RCTs, we were particularly interested in the real-
life effectiveness of extrafine BDP/F in adult asthmatics
according to their smoking status.Methods
Study objectives
This was a Phase IV, observational, non-interventional,
prospective, open-label, multicentre study. Its primary
objective was to describe the patients who were being
treated with extrafine BDP/F in terms of demographics,
diagnosis and clinical stage of asthma, level of asthma
control, treatment history and concomitant asthma medi-
cations. The secondary objectives were to assess the
effectiveness and safety of extrafine BDP/F over 12 months
in terms of asthma control in patients with persistent
asthma. Asthma control was assessed by using the GINA
classification (investigator’s perspective) and the Asthma
Control Questionnaire (ACQ) (patient’s perspective).19,20
Pulmonary function was determined, as per routine prac-
tice, using the percentage of predicted forced expiratory
volume in 1 s (FEV1 % pred) or the peak expiratory flow
(PEF) absolute value. All pulmonary function measurements
were performed pre-bronchodilator. Spontaneously repor-
ted adverse drug reactions (ADRs) and serious adverse drug
reactions (SADRs) were coded using the Medical Dictionary
for Regulatory Affairs (MedDRA). The reduction in ICS dose
(expressed as extrafine BDP equivalents in accordance with
Figure 1 Patient flow chart.
Extrafine BDP/F in persistent asthma 813Paggiaro21: 100 mg of BDP in extrafine HFA formulation was
equivalent to 250 mg of BDP in traditional chlorofluoro-
carbon [CFC] formulation) was calculated.
The study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice. It was
approved by the Ethical Committee of the Ghent University
Hospital, Ghent, Belgium, and by all local ethical commit-
tees of involved investigational centres. All patients
participating in the study provided written informed
consent.
Study design
The decision to prescribe BDP/F had been made by the
physician (pneumologist or general practitioner [GP])
independently of his/her decision to include the patient in
the study. The inclusion criteria were as follows: Man or
woman aged at least 18 years with moderate-to-severe
persistent asthma in which a combination of ICS and LABA
was indicated. The diagnosis of asthma was confirmed
according to the American Thoracic Society definition.22
The exclusion criteria were as follows: Pregnant or
lactating woman, hypersensitivity and/or allergy to BDP/F
and/or any other ingredient of the drug, and contraindi-
cations to beta2-agonists.
The patients were to be followed as per usual clinical
practice. Three visits were proposed in accordance with
real-life practice: an inclusion visit, a second visit after 2e8
months and a third visit after >8 up to 14 months. If
additional visits were performed, data were only registered
in case of change in asthma medication, drop-out, drug
discontinuation or ADRs/SADRs.
Statistics
Due to the observational nature of this trial and the non-
comparative design, there was no ethical or statistical
concern linked to the sample size. It was thus preferable to
include as many patients as possible in order to obtain the
most representative and complete set of data.
A planned sample size of 660 patients was thus only
based on the expected capacity to recruit patients in GPs
and pneumologists (around 100 investigators in total) from
Belgium within approximately 12 months.
Two groups were considered for the analyses: patients
who were previously not well controlled on ICS only and
who were stepped-up to BDP/F and patients who were
already on ICS þ LABA treatment. Predefined subgroup
analyses separating current or former smokers, and non-
smokers were also made.
The statistical analysis was essentially descriptive. Non-
smokers and smokers (former or current) were compared
using independent Student’s t tests, Fisher’s exact tests
and chi-square tests. Inferential statistics were also used to
compare the efficacy of extrafine BDP/F at the three time
points. Paired Student’s t test were used to assess the over-
time modification of the pulmonary function, ACQ6 (6
questions) and ACQ7 (6 first questions plus FEV1% pred or
PEF absolute value) at the three time points. The modifi-
cation of asthma control as a function of GINA criteria was
compared between the three time points using chi-squaretests. p values lower than 0.05 were considered statistically
significant. Drop-outs or withdrawals were not replaced.
Missing values were not replaced, nor extrapolated. IBM
SPSS Statistics (Version 19.0, Chicago, Illinois, USA) was
used throughout the statistical analyses.
Results
Number of patients enrolled and attrition from the
study
Overall, 619 patients (Safety cohort) with persistent asthma
were included by 97 investigators in Belgium: 291 patients
were recruited by 34 pneumologists and 328 patients were
recruited by 63 GPs. A total of 568 patients (Effectiveness
cohort) had ACQ6 data at baseline and were available for
the effectiveness analyses: 370 patients participated in
Visit 2 (61e240 days after inclusion; meanZ 168 days) and
340 patients completed the study (Visit 3; >240 days after
inclusion; mean Z 358 days). A total of 143 patients were
lost to follow-up and 52 patients prematurely discontinued
the study (Fig. 1): 18 patients (3.17%) prematurely dis-
continued the study for Adverse Events (AEs) or Adverse
Drug Reactions (ADRs), encompassing palpitations (5
patients), oral candidiasis (3 patients), cough (1 patient),
dyspepsia (1 patient) and other reasons (7 patients). One
patient, a 75 year-old male smoker with diabetes, suffered
from a cerebrovascular accident leading to aspiration
pneumonia and death; this serious adverse event (SAE) was
considered to be not related to the study drug.
Demographics and baseline characteristics
Demographics and baseline characteristics of the patient
population (effectiveness cohort, non-smokers and smokers)
are described in Table 1. The majority of patients were
Caucasian (97.7%). The smoking status was as follows: 445
non-smokers and 123 smokers (current smokers þ patients
having stopped smoking for less than 1 year).
ACQ7 score was 2.23  1.13 and ACQ6 score was
2.19  1.17. Considering the fact that the majority of
patients (79.8%) were already on maintenance treatment
Table 1 Demographics and baseline characteristics of the patient population (patients with ACQ6 measured at baseline
[N Z 568], non-smokers and smokers [former or current]).
Total cohort with
ACQ6 at baseline
Non-smokers
(N Z 445)
Smokers (N Z 123) p-value
N Mean SD N Mean SD N Mean SD
Age (year) 568 48.6 16.9 445 50.2 17.0 123 42.7 15.6 <0.0001
Asthma duration (year) 461 11.9 15.6 362 12.1 15.8 96 10.9 15.0 0.511
Age at onset of asthma (year) 461 36.4 20.1 362 37.8 20.6 96 31.2 17.4 0.002
FEV1 % pred 368 78.6 19.7 277 79.4 19.9 86 76.4 19.6 0.225
PEF absolute value (l/min) 89 269 189 70 276 192 19 243 180 0.502
ACQ7 395 2.23 1.13 300 2.14 1.17 92 2.51 0.96 0.002
ACQ6 568 2.19 1.17 445 2.11 1.19 123 2.50 1.03 <0.0001
N % N % N %
Gender 568 445 123
Female 305 53.7 231 51.9 74 60.2 0.126
Male 263 46.3 214 48.1 49 39.8
Control of asthmaa 568 445 123
Controlled 33 5.8 32 7.2 1 0.8
Partially controlled 419 73.8 319 71.7 100 81.3
Uncontrolled 80 14.1 62 13.9 18 14.6 0.021
Missing information 36 6.3 32 7.2 4 3.3
FEV1% pred Z Predicted percentage of forced expiratory volume in 1 s; PEF Z Peak Expiratory Flow; ACQ Z Asthma Control Ques-
tionnaire.
Statistical comparisons between non-smokers and smokers (p values): Independent Student’s t tests for continuous variables, Fisher’s
exact test for gender and chi-square test for control of asthma according to GINA.
a According to GINA Z Global Initiative for Asthma.
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814 G. Brusselle et al.for asthma, the pulmonary function measurements and ACQ
scores were indicative of a population with moderate-to-
severe asthma.
Overall, smokers tended to have lower pulmonary
function (FEV1 % pred [p > 0.05] and PEF [p > 0.05]) and
worse asthma control (ACQ6 [p < 0.0001], ACQ7
[pZ 0.002] and GINA classification [pZ 0.021]) at baseline
compared to non-smokers (Table 1).
Overall, 453 (79.8%) patients were reported to be
already on asthma treatment. In 23.2% of patients it cor-
responded to a step-up treatment (replacement of ICS) and
in 72.2% of patients BDP/F replaced another combination of
ICS þ LABA.
Other pathologies in relation with asthma were recorded
in 172 patients (30.3%). The predominant co-morbidities
were allergy (64.5%) and chronic bronchitis, chronic
obstructive pulmonary disease or emphysema (6.3%).50
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Figure 2 Pulmonary function measured by spirometry:
percentage of predicted forced expiratory volume in 1 s (FEV1%
pred) at baseline, visit 2 (after 6 months of treatment) and
visit 3 (after 12 months of treatment) (mean  standard
deviation; paired Student’s t tests; */*/*p < 0.0001 versus
baseline for all patients, non-smokers and active/former
smokers, respectively).Real-life effectiveness of extrafine BDP/F HFA
In the effectiveness cohort, extrafine BDP/F induced
a significant improvement of the pulmonary function
measured as FEV1 % pred (increase of 8.1% and 7.1% at Visits
2 and 3, respectively [p < 0.0001]) (Fig. 2) or as PEF
absolute value (increase of 90.7 l/min at Visit 2 [pZ 0.067]
and 113.2 l/min at Visit 3 [p Z 0.002]) (Fig. 3), during the
entire period of observation. The ACQ7 (Fig. 4) and ACQ6
(Fig. 5) scores, completed by the patients, significantly
improved by 1.16 and 1.22 unit (p < 0.0001) at Visit 2 and
by 1.17 and 1.32 unit (p < 0.0001) at Visit 3, respectively.The minimum clinically important difference (MCID) in the
ACQ scores is considered to be 0.5 unit.20 The control of
asthma as judged by the treating physicians according to
the GINA criteria, also improved significantly: 92.0% of
patients maintained (42.2%) or improved (49.8%) asthma
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Figure 3 Pulmonary function measured by peak flow: peak
expiratory flow (l/min) at baseline, visit 2 (after 6 months of
treatment) and visit 3 (after 12 months of treatment)
(mean  standard deviation; paired Student’s t tests;
*p Z 0.002 versus baseline).
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Figure 5 Asthma Control Questionnaire (ACQ6; 6 first ques-
tions) at baseline, visit 2 (after 6 months of treatment) and
visit 3 (after 12 months of treatment) (mean  standard
deviation; paired Student’s t tests; */*/*p < 0.0001 versus
baseline for all patients, non-smokers and active/former
smokers, respectively).
Extrafine BDP/F in persistent asthma 815control at Visit 3 (p < 0.0001) (Fig. 6). Importantly, there
was a reduction in the dose of ICS from 489  192 mg BDP
extrafine equivalents at baseline to 273  122 mg at Visit 2
and 265  125 mg at Visit 3 under treatment with extrafine
BDP/F (Fig. 7). In Figs. 8 and 9, the effectiveness of
extrafine BDP/F HFA on pulmonary function (FEV1 %pred)
and on asthma control (ACQ6) is shown according to the
maintenance treatment at baseline: either ICS mono-
therapy or another combination of ICS þ LABA.
Effectiveness of extrafine BDP/F HFA in smoking
asthmatics
In the cohort of smokers (former or current), FEV1 % pred
increased significantly by 8.3% (p < 0.0001) and 5.1%
(p < 0.0001) at Visit 2 and Visit 3, respectively (Fig. 2). PEF
was measured in a too small number of patients to stratify
the analysis by smoking status. ACQ7 and ACQ6 decreased0
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Figure 4 Asthma Control Questionnaire (ACQ7; 6
questions þ FEV1% pred or PEF % pred) at baseline, visit 2
(after 6 months of treatment) and visit 3 (after 12 months
of treatment) (mean  standard deviation; paired Student’s t
tests; */*/*p < 0.0001 versus baseline for all patients, non-
smokers and active/former smokers, respectively).significantly by 1.1 and 1.3 unit at Visit 2 (p < 0.0001), and
by 1.2 and 1.3 unit at Visit 3 (p < 0.0001), respectively
(Figs. 4 and 5). Approximately 91% of patients maintained
(44.4% and 42.6%) or improved (45.8% and 47.5%) asthma
control according to GINA criteria at Visit 2 (pZ 0.127) and
Visit 3 (p Z 0.016), respectively. All comparisons between
smokers and non-smokers in terms of outcome measures of
effectiveness (pulmonary function, patient-completed ACQ
and physician-judged control of asthma according to GINA
criteria) did not reveal any significant differences in ther-
apeutic response to BDP/F HFA pMDI (p > 0.05).
Safety
In the safety cohort (NZ 619), 16 ADRs were reported by 15
patients (2.42%). The majority of these ADRs were in line
with the Summary of Product Characteristics of BDP/F HFA
pMDI. In particular, palpitations (N Z 5) and headache
(N Z 1) are well-known side effects of LABA and oral/
oesophageal candidiasis (N Z 5) are well-known side
effects of ICS. Serious adverse events were reported in 3
patients, but none was considered related to the investi-
gational drug. All together, 22 patients (3.55%) prematurely
discontinued the study for adverse events or ADRs.
Discussion
This prospective one-year observational cohort study in
adult asthmatics clearly demonstrates the real-life effec-
tiveness of extrafine BDP/F (100/6 mg) HFA pMDI, leading to
clinically and statistically significant improvements in
pulmonary function (þ7 to þ8%) and asthma control, as
evaluated by the patient (ACQ6: 1.2 to 1.3) or rated by
the treating physician (according to the GINA criteria)
(improvement in asthma control in 49.8% of patients).
However, since spirometry was measured during the
follow-up in only a part of the subjects, the observation of
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Figure 6 Comparison of the control of asthma according to the Global Initiative for Asthma (GINA) criteria between baseline and
visit 2 (after 6 months of treatment) as well as between baseline and visit 3 (after 12 months of treatment) (number of patients
at each visit; % of patients; Chi-square tests).
816 G. Brusselle et al.the improvement in FEV1 should be interpreted with
caution.
Importantly, smoking asthmatics had lower pulmonary
function and worse asthma control at baseline compared to
non-smoking asthmatics, which corroborates the observa-
tions made in other studies.3,23,24 However, our study
clearly demonstrates that the absolute improvements in
lung function and asthma control upon treatment with
extrafine BDP/F HFA are similar in magnitude in both
smoking and non-smoking asthmatics.
The majority of patients suffering from moderate-to-
severe asthma, were partially controlled (73.8%), and were0
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Figure 7 Over-time modification of the ICS dose (in mg
beclometasone dipropionate [BDP] extrafine equivalents)
between baseline (before starting the treatment with extrafine
BDP/formoterol 100/6 mg) and visit 2 (after 6 months of
treatment), and visit 3 (after 12 months of treatment)
(number of patients at each visit; mean  standard deviation).
The surface delimited with dotted lines at baseline represents
the ICS dose of chlorofluorocarbon-BDP non-extrafine equiva-
lent (2.5 times the BDP extrafine dose).already treated with a fixed combination of ICS and LABA
for most cases (72.2%). The patient population included in
this study is representative of the asthmatic population in
Belgium in terms of age (48 years), gender (slight
predominance of women), age at onset of asthma (36
years), asthma duration (12 years) and smoking status
(22% former or current smokers).23,25
ICS are known to be less effective in smokers than in
non-smokers.26,27 Interestingly, in the current study, the
same benefits, in improving pulmonary function and asthma
control, were also demonstrated in smokers (former or
current), who are mostly excluded from RCTs. This
improvement could be related to the drug particle size,
which results in improved lung deposition and allows for
uniform treatment of inflammation and bronchocon-
striction throughout the entire bronchial tree,5e8 without
increasing systemic load.21,28 In the START study, an
improvement has also been observed in a subset of smoking
patients with mild persistent asthma, in whom the benefits
of therapy with budesonide in preventing lung function
decline were similar in smokers and non-smokers.29 The
results of our study extend this observation to extrafine
BDP/F used to treat smoking patients with moderate-to-
severe persistent asthma.
Pharmacokinetic and pharmacodynamic characteristics
that can enhance the efficacy of ICS include small particle
size, high glucocorticoid receptor binding affinity, long-
lasting pulmonary residence time and lipid conjugation.30
During the course of this study, the BDP extrafine equiva-
lent dose (calculated in accordance with Paggiaro21: 100 mg
of BDP in extrafine HFA formulation is equivalent to 250 mg
of BDP in traditional CFC formulation) decreased by 45%.
This is also an important objective to achieve in order to
limit the burden of chronic treatment with ICS in asthma
care.3 Safety of ICS is further increased in case of on-site
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Figure 8 Pulmonary function measured by spirometry: percentage of predicted forced expiratory volume in 1 s (FEV1% pred) at
baseline, visit 2 (after 6 months of treatment) and visit 3 (after 12 months of treatment) in patients who stepped-up from an ICS
to extrafine BDP/F HFA or who received extrafine BDP/F HFA in replacement of another ICS þ LABA (mean  standard deviation;
paired Student’s t tests; *p Z 0.002 versus baseline and **p < 0.0001 versus baseline).
Extrafine BDP/F in persistent asthma 817activation in the lung, low oropharyngeal exposure, negli-
gible oral bioavailability and rapid systemic clearance.30
Extrafine BDP/F was well-tolerated in our cohort study.
ADRs were in line with the well-known effects of formoterol
and beclometasone.
Previously published RCTs found no differences between
the effect of extrafine BDP/F and budesonide/formoterol
or fluticasone/salmeterol on pulmonary function, use of
rescue medications, exacerbations and safety.12,13 In the0
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Figure 9 Asthma Control Questionnaire (ACQ6) as filled in by
the patient at baseline, visit 2 (after 6 months of treatment)
and visit 3 (after 12 months of treatment) in patients who
stepped-up from an ICS to extrafine BDP/F HFA or who received
extrafine BDP/F HFA in replacement of another ICS þ LABA
(mean  standard deviation; paired Student’s t tests;
*p < 0.0001 versus baseline).real-life study of Muller et al.1patients treated with
extrafine BDP/F achieved a greater level of asthma control
as compared to patients treated with fluticasone/salme-
terol and budesonide/formoterol larger particle size
combinations. The results of the present study indirectly
corroborate those of Muller et al.1 and suggest that higher
deposition of extrafine particles in the small airways might
be contributing to these beneficial effects, particularly in
smoking asthmatics.
Observational studies in large populations are useful to
complement the findings from RCTs by assessing treatment
effectiveness and safety in patients encountered in daily
clinical practice.4,15e18 Because observational studies do
not exclude asthma patients who are smoking or who have
co-morbidities, the present study contributes to a better
assessment of the real-life effectiveness and safety of
extrafine BDP/F (100/6 mg) in patients suffering from
moderate-to-severe persistent asthma. However, the limi-
tations of this observational study are also inherent to its
design: no comparative data, no active patient follow-up,
no data on treatment adherence, no measure of asthma
exacerbations. In the present study, the drop-out rate is
high (comparable in pneumologists and GPs), in particular
between baseline and Visit 2 (30%), but much less between
Visit 2 and Visit 3 (5%). The high rate of withdrawal may
have selected more compliant patients with better
outcomes from a more strict follow-up.
For a long time, observational studies were considered
to overestimate the magnitude of treatment effects
compared to RCTs. Literature reviews, covering 99 reports
in 5 therapeutic areas on one hand and 136 reports for 19
diverse treatments on the other hand, among which
asthma, tend to show that this is not the case.31,32
However, we cannot make firm conclusions concerning
a causal relationship of the observed associations in our
study due to the observational study design.
818 G. Brusselle et al.In conclusion, the results of this large observational
study demonstrate the real-life effectiveness and safety of
extrafine fixed combination of BDP/F (100/6 mg) in adult
patients with moderate-to-severe persistent asthma,
encompassing statistically and clinically important
improvements in pulmonary function and asthma control,
despite a significant reduction in ICS dose. Interestingly,
they also extend the same conclusions to smoking asth-
matic patients.
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